摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,1,1,2,2,3,3,4,4,5,5-十一氟-5-[1,1,2,3,3,3-六氟-2-(三氟甲基)丙氧基]戊烷 | 169477-62-7

中文名称
1,1,1,2,2,3,3,4,4,5,5-十一氟-5-[1,1,2,3,3,3-六氟-2-(三氟甲基)丙氧基]戊烷
中文别名
——
英文名称
2-trifluoromethylheptadecafluoro-4-oxanonane
英文别名
1,1,1,2,2,3,3,4,4,5,5-Undecafluoro-5-[1,1,2,3,3,3-hexafluoro-2-(trifluoromethyl)propoxy]pentane
1,1,1,2,2,3,3,4,4,5,5-十一氟-5-[1,1,2,3,3,3-六氟-2-(三氟甲基)丙氧基]戊烷化学式
CAS
169477-62-7
化学式
C9F20O
mdl
——
分子量
504.066
InChiKey
ODWOZMSHTDFDFA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    113.8±40.0 °C(Predicted)
  • 密度:
    1.721±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    7.2
  • 重原子数:
    30
  • 可旋转键数:
    6
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    21

安全信息

  • 危险品标志:
    Xi

反应信息

  • 作为产物:
    描述:
    2,5,5,9-tetrahydro-2-trifluoromethylundecafluoro-4-oxanonane 在 nickel(II) fluoride 、 fluorine 作用下, 以66%的产率得到1,1,1,2,2,3,3,4,4,5,5-十一氟-5-[1,1,2,3,3,3-六氟-2-(三氟甲基)丙氧基]戊烷
    参考文献:
    名称:
    Zakharov, V. Yu.; Denisov, A. K.; Novikova, M. D., Russian Journal of Organic Chemistry, 1994, vol. 30, # 12, p. 1942 - 1945
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • METHOD FOR SEPARATING CARBOXYLIC ACID COMPOUND CONTAINING PERFLUORO(POLY)ETHER GROUP
    申请人:Daikin Industries, Ltd.
    公开号:EP3037455A1
    公开(公告)日:2016-06-29
    A problem of the present invention is to provide a method of isolating perfluoro(poly)ether group-containing carboxylic acid compounds. The method of the present invention is a method of isolating, from a mixture comprising a perfluoro(poly)ether group-containing compound; and a perfluoro(poly)ether group-containing monocarboxylic acid compound or a perfluoro(poly)ether group-containing dicarboxylic acid compound, the above carboxylic acid compounds. The method comprises the steps of mixing the mixture, a fluorine atom-containing nonpolar solvent, and a polar stationary phase with each other, isolating the perfluoro(poly)ether group-containing compound from the polar stationary phase using a nonpolar mobile phase, and isolating the carboxylic acid compound from the polar stationary phase using the polar mobile phase. The nonpolar mobile phase comprises a fluorine atom-containing nonpolar solvent, and the polar mobile phase comprises a fluorine atom-containing polar solvent, comprises a combination of a fluorine atom-containing nonpolar solvent and a fluorine atom-containing polar solvent, or comprises a combination of a fluorine atom-containing nonpolar solvent and a fluorine atom-non-containing polar solvent.
    本发明的一个问题是提供一种分离含全氟(多)醚基羧酸化合物的方法。本发明的方法是从一种混合物中分离出上述羧酸化合物的方法,该混合物包括一种含全氟(多)醚基的化合物;和一种含全氟(多)醚基的单羧酸化合物或一种含全氟(多)醚基的二羧酸化合物。该方法包括以下步骤:将混合物、含原子的非极性溶剂和极性固定相相互混合,使用非极性流动相从极性固定相中分离出含全氟(多)醚基化合物,使用极性流动相从极性固定相中分离出羧酸化合物。非极性流动相包括含原子的非极性溶剂,极性流动相包括含原子的极性溶剂,包括含原子的非极性溶剂和含原子的极性溶剂的组合,或包括含原子的非极性溶剂和不含原子的极性溶剂的组合。
  • ISOLATION AND PURIFICATION METHOD OF PERFLUOROPOLYETHER COMPOUND
    申请人:Shin-Etsu Chemical Co., Ltd.
    公开号:EP3578585A1
    公开(公告)日:2019-12-11
    Provided is a method for efficiently and selectively isolating only a perfluoropolyether compound having a target functional group(s) from a mixture containing at least two kinds of perfluoropolyether compounds. The method is thus an isolation and purification method of a perfluoropolyether compound. This method is a method for isolating and purifying a perfluoropolyether compound which is contained in a mixture containing at least two kinds of perfluoropolyether compounds, and has at molecular chain ends thereof only functional groups that are nonreactive with primary amino groups. The method of the present invention includes: preparing: (A) the perfluoropolyether compound having, at molecular chain ends thereof, only functional groups that are nonreactive with primary amino groups, and having the number average molecular weight of 1,000 to 10,000, (B) the perfluoropolyether compound having, at at least one molecular chain end thereof, functional groups that are reactive with or are capable of forming salts with primary amino groups, and having the number average molecular weight of 1,000 to 10,000, and (C) the primary amino group-containing solid adsorbent; bringing the primary amino group-containing solid adsorbent (C) into contact with the mixture containing the perfluoropolyether compound (A) and the perfluoropolyether compound (B); removing, from said mixture, the perfluoropolyether compound (B) that has been adsorbed to the solid adsorbent (C); and then collecting the perfluoropolyether compound (A) having, at molecular chain ends thereof, only functional groups that are nonreactive with primary amino groups.
    本发明提供了一种方法,可从含有至少两种全氟聚醚化合物的混合物中高效、选择性地仅分离出一种具有目标官能团的全氟聚醚化合物。 因此,该方法是一种全氟聚醚化合物的分离和纯化方法。本方法是一种分离和纯化全氟聚醚化合物的方法,该化合物包含在含有至少两种全氟聚醚化合物的混合物中,其分子链末端仅具有与伯基不反应的官能团。本发明的方法包括 制备: (A) 全氟聚醚化合物,其分子链末端仅具有与伯基不反应的官能团,且平均分子量在 1,000 至 10,000 之间、 (B) 在其至少一个分子链末端具有与伯基反应或能与伯基形成盐的官能团,且平均分子量为 1,000 至 10,000 的全氟聚醚化合物,以及 (C) 含伯基的固体吸附剂; 使含伯基的固体吸附剂(C)与含有全氟聚醚化合物(A)和全氟聚醚化合物(B)的混合物接触; 从所述混合物中除去吸附在固体吸附剂(C)上的全氟聚醚化合物(B);然后 收集分子链末端仅具有与伯基不反应的官能团的全氟聚醚化合物 (A)。
  • Novel aerosol formulation containing a polar fluorinated molecule
    申请人:——
    公开号:US20030194378A1
    公开(公告)日:2003-10-16
    The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar flurorinated molecule and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture thereof.
    本发明涉及一种用于吸入的稳定药用气溶胶制剂。该制剂含有一种活性物质、一种气溶胶推进剂、一种极性化分子和一种赋形剂。优选的推进剂是 HFA 134a 或 HFA 227 或它们的混合物。
  • NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE
    申请人:AstraZeneca AB
    公开号:EP1303258A1
    公开(公告)日:2003-04-23
  • [EN] NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE<br/>[FR] NOUVELLE PREPARATION EN AEROSOL CONTENANT UNE MOLECULE FLUOREE POLAIRE
    申请人:ASTRAZENECA AB
    公开号:WO2002003958A1
    公开(公告)日:2002-01-17
    The present invention relates to a stable pharmaceutical aerosol formulation intended for inhalation. The formulation contains an active substance, an aerosol propellant, a polar flurorinated molecule and an excipient. The preferred propellant is HFA 134a or HFA 227 or a mixture thereof.
查看更多